Trial · NCT04634409
Participant flow108
How many started, completed or left each group, period by period.
1 to 20 of 108
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment 1: Pbo | 155 | |
| Overall Study | STARTED | Treatment 2: 175 mg BAM +350 mg ETE | 83 | |
| Overall Study | STARTED | Treatment 3: 700 mg BAM +1400 mg ETE | 158 | |
| Overall Study | STARTED | Treatment 4: 2800 mg BAM +2800 mg ETE | 103 | |
| Overall Study | STARTED | Treatment 5: 700 mg BAM | 105 | |
| Overall Study | STARTED | Treatment 6: 350 mg BAM +700 mg ETE | 101 | |
| Overall Study | STARTED | Unintentional Dosing: 700 mg BAM +700 mg ETE | 20 | |
| Overall Study | STARTED | Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e)) | 101 | |
| Overall Study | STARTED | Treatment 8: Pbo For 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e)) | 101 | |
| Overall Study | STARTED | Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants) | 125 | |
| Overall Study | STARTED | Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants) | 127 | |
| Overall Study | STARTED | Treatment 11: Pbo For 175 mg BEB & 700 mg BAM +1400 mg ETE +175 mg BEB (Low Risk Participants) | 128 | |
| Overall Study | STARTED | Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants) | 100 | |
| Overall Study | STARTED | Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants) | 50 | |
| Overall Study | STARTED | Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB(Amendment (g), High Risk,Updated CDC Criteria) | 176 | |
| Overall Study | STARTED | 700 mg BAM 15-min (Addendum (2)) | 30 | |
| Overall Study | STARTED | 700 mg BAM + 1400 mg ETE 30-min (Addendum (2)) | 6 | |
| Overall Study | STARTED | 700 mg BAM + 1400 mg ETE 15-min (Addendum (2)) | 30 | |
| Overall Study | STARTED | Pooled Placebo (Addendum 4, IV) | 10 | |
| Overall Study | STARTED | 70 mg BEB 140 mg/Min (Addendum 4, IV) | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04634409/flow